Bristol Claims A First With Opdivo In Neoadjuvant NSCLC
Co-Primary Endpoint Data May Support Early Approval
More lung cancer patients treated with neoadjuvant Opdivo plus chemotherapy had a pathologic complete response than those who received chemo alone. BMS will discuss the results with regulators.
You may also be interested in...
With new Opdivo/Yervoy combination data in first-line lung cancer, the company expects the PD-1 inhibitor’s growth to go from flat to rising in 2021. Bristol’s and Celgene’s third quarter earnings exceeded expectations and their merger is on track to close this year.
Better than expected FDA labeling for rising star Perjeta in neoadjuvant (before surgery) and adjuvant (after surgery) breast cancer could boost sales greatly beyond expectations, some analysts say.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.